Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071929
Status:
COMPLETED
Last Update Posted:
2013-06-24
First Post:
2003-11-04
Brief Title:
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
Sponsor:
Gynecologic Oncology Group
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Evaluation of Oxaliplatin in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status:
COMPLETED
Status Verified Date:
2004-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as oxaliplatin work in different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of oxaliplatin in treating patients who have persistent or recurrent endometrial cancer
PURPOSE Phase II trial to study the effectiveness of oxaliplatin in treating patients who have persistent or recurrent endometrial cancer
Detailed Description:
OBJECTIVES
Determine the antitumor activity of oxaliplatin in terms of response rate in patients with persistent or recurrent endometrial carcinoma that is refractory to curative or established therapy
Determine the nature and degree of toxicity of this treatment regimen in these patients
OUTLINE This is a multicenter study
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL Approximately 19-51 patients will be accrued for this study
Determine the antitumor activity of oxaliplatin in terms of response rate in patients with persistent or recurrent endometrial carcinoma that is refractory to curative or established therapy
Determine the nature and degree of toxicity of this treatment regimen in these patients
OUTLINE This is a multicenter study
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL Approximately 19-51 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOG-0129K | None | None | None |